长链非编码RNA UCA1与抗癌药物耐药性
LncRNA UCA1 in anti-cancer drug resistance.
作者信息
Wang Haohao, Guan Zhonghai, He Kuifeng, Qian Jiong, Cao Jiang, Teng Lisong
机构信息
Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China.
Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang, P.R. China.
出版信息
Oncotarget. 2017 Jun 2;8(38):64638-64650. doi: 10.18632/oncotarget.18344. eCollection 2017 Sep 8.
The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.
长链非编码RNA（lncRNA）尿路上皮癌相关1（UCA1）在抗癌药物耐药性中的关键作用已在多种癌症中得到证实。lncRNA UCA1的过表达与对顺铂、吉西他滨、5-氟尿嘧啶、他莫昔芬、伊马替尼和表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）等化疗药物的耐药性相关，而lncRNA UCA1的敲低可恢复药物敏感性。这些研究突出了lncRNA UCA1作为恶性肿瘤诊断和预后生物标志物以及治疗靶点的潜力。在本综述中，我们阐述了lncRNA UCA1在抗癌药物耐药性中的作用，并讨论了其在未来临床应用中的潜力。
相似文献
Oncotarget. 2017-6-2
J Cancer Res Clin Oncol. 2016-7
Cancer Chemother Pharmacol. 2016-5
Rev Assoc Med Bras (1992). 2019-3
Biomed Pharmacother. 2016-10
引用本文的文献
Naunyn Schmiedebergs Arch Pharmacol. 2025-1-18
Noncoding RNA. 2024-9-30
Iran J Public Health. 2024-4
Med Oncol. 2024-10-21
Noncoding RNA Res. 2024-4-4
Antibiotics (Basel). 2024-2-27
本文引用的文献
Clin Transl Oncol. 2017-6
Eur Rev Med Pharmacol Sci. 2016-10
Cancer Chemother Pharmacol. 2016-11
Zotero 插件